List of Excipients in Branded Drug LIBTAYO

« Back to Dashboard

Last updated: September 24, 2026

Executive summary: LIBTAYO (cemiplimab-rwlc) uses a conventional liquid monoclonal-antibody formulation built around histidine buffering, sucrose stabilization, and polysorbate 80 for interfacial protection. The formulation is commercially validated, but its excipient profile leaves opportunities in subcutaneous delivery, reduced-volume administration, ready-to-use presentations, container-closure systems, and biosimilar manufacturing support. The key commercial constraint is that LIBTAYO is a biologic, so biosimilar competition will depend on BLA exclusivity, patent scope, analytical comparability, clinical interchangeability, and manufacturing economics rather than on a conventional small-molecule generic pathway.

LIBTAYO Excipient Strategy, Formulation Patents, Biosimilar Risk, and Commercial Opportunities

What is the LIBTAYO formulation and which excipients does it contain?

LIBTAYO is an intravenous formulation of cemiplimab-rwlc, a fully human IgG4 monoclonal antibody targeting PD-1. The marketed product is supplied as a sterile, preservative-free, single-dose vial containing 350 mg in 7 mL, equivalent to 50 mg/mL.

Formulation attribute	LIBTAYO specification
Active ingredient	Cemiplimab-rwlc
Dosage form	Sterile intravenous solution
Strength	350 mg/7 mL
Concentration	50 mg/mL
Vial type	Single-dose vial
Buffer system	L-histidine and L-histidine hydrochloride monohydrate
Tonicity and stabilization	Sucrose
Surfactant	Polysorbate 80
Diluent	0.9% sodium chloride or 5% dextrose injection
Administration	Intravenous infusion over approximately 30 minutes
Preservatives	None reported in the U.S. prescribing information
FDA application	BLA 761097

The formulation uses a standard antibody-development architecture:

1. Histidine provides pH control.
2. Sucrose limits aggregation and protects the antibody during freezing, thawing, shipping, and agitation.
3. Polysorbate 80 reduces adsorption and interface-induced aggregation at the vial, tubing, and infusion-bag surfaces.
4. Water for injection provides the liquid vehicle.

The U.S. label identifies a formulation pH of approximately 6.0. The product is diluted before administration and is not intended for bolus injection or intramuscular use (U.S. Food and Drug Administration [FDA], 2024).

Why does LIBTAYO use histidine, sucrose, and polysorbate 80?

The excipient system is designed to protect a concentrated IgG4 molecule through manufacturing, storage, dilution, and intravenous administration.

Histidine buffer

Histidine is widely used in antibody formulations because it provides useful buffering capacity near mildly acidic pH values while maintaining acceptable compatibility with proteins and parenteral administration. For cemiplimab, a mildly acidic formulation may reduce chemical and physical degradation compared with a neutral-pH system.

The commercial opportunity around histidine is limited as a standalone product because it is a common excipient. Its value is higher in qualified pharmaceutical grades, validated supplier networks, low-endotoxin production, and supply continuity for biologics manufacturers.

Sucrose

Sucrose acts primarily as a nonreducing stabilizer and tonicity modifier. It can reduce conformational stress and aggregation during temperature excursions, freezing, thawing, and mechanical handling. Sucrose is generally more attractive than some alternative sugars because it has extensive parenteral precedent and does not introduce the reducing chemistry associated with certain monosaccharides.

Potential formulation-development work includes:

• Sucrose concentration optimization.
• Substitution with trehalose or other nonreducing sugars.
• Improved stability under repeated agitation.
• Compatibility with high-concentration subcutaneous formulations.
• Reduced viscosity and lower injection force for alternative delivery.

A biosimilar developer does not need to reproduce sucrose exactly if the final product demonstrates appropriate quality, safety, and performance. The reference formulation remains the benchmark for analytical comparability and clinical risk assessment.

Polysorbate 80

Polysorbate 80 protects the antibody from surface adsorption and agitation-related aggregation. It is also a known source of formulation risk. Degradation can generate peroxides and other species that may contribute to protein oxidation, particulate formation, or loss of product quality.

Commercial and technical opportunities include:

• Higher-purity polysorbate 80 grades.
• Low-peroxide and low-impurity materials.
• Improved oxidation-control strategies.
• Alternative surfactants such as polysorbate 20 or poloxamers.
• Analytical methods for monitoring surfactant degradation and protein oxidation.
• Container and tubing compatibility programs.

A change from polysorbate 80 to another surfactant would normally require a substantial comparability package. The substitution could affect aggregation, particles, immunogenicity risk, extractables, leachables, and shelf life.

What commercial opportunities exist in LIBTAYO excipients and drug delivery?

The strongest opportunities are not likely to come from copying the existing excipient list. They are more likely to arise from improving administration, stability, supply security, or manufacturing efficiency.

Opportunity	Commercial rationale	Main barrier
Pharmaceutical-grade histidine	Reliable supply for antibody manufacturers	Commodity pricing and multiple suppliers
Low-peroxide polysorbate 80	Reduces oxidation and particulate risk	Supplier qualification and long-term stability
Alternative surfactants	May improve oxidation or high-concentration stability	Comparability and clinical bridging
Ready-to-administer bags or syringes	Reduces pharmacy preparation time	Container closure, stability, and aseptic filling
High-concentration formulation	Supports lower-volume or subcutaneous delivery	Viscosity, aggregation, injection force
Subcutaneous delivery	Could expand administration settings and reduce infusion burden	Device compatibility and new clinical development
Lyophilized product	May improve shipping or long-term stability	Reconstitution burden and manufacturing cost
Single-use closed-system transfer	Reduces contamination and occupational exposure risk	Hospital adoption and device validation
Biosimilar formulation services	Supports analytical and CMC development	Competitive CRO and CDMO market
Specialty packaging	Protects against light, freezing, and agitation	Incremental value depends on clinical need

The most commercially important opportunity is a subcutaneous or lower-volume presentation. LIBTAYO is currently an intravenous oncology product, so the existing administration model requires an infusion center, pharmacy preparation, nursing time, and patient chair time. A subcutaneous product could support outpatient oncology, home-adjacent care, or shorter clinic visits if clinical efficacy, safety, immunogenicity, and delivery-device requirements are satisfied.

That opportunity has technical limits. Antibodies at high concentration can become viscous, aggregate, or show elevated injection force. A formulation suitable for a 350 mg intravenous vial may not be suitable for a prefilled syringe, autoinjector, or wearable injector.

What formulations are protected by LIBTAYO-related intellectual property?

The relevant intellectual-property categories include:

• Cemiplimab composition-of-matter claims.
• Antibody sequence and binding-site claims.
• Formulation claims covering antibody concentration, pH, buffer, sugar, and surfactant combinations.
• Stability claims covering liquid storage and aggregation control.
• Methods of treating cancers with cemiplimab.
• Manufacturing and purification claims.
• Combination-treatment claims involving chemotherapy, radiotherapy, or other immuno-oncology agents.
• Device and container-closure claims, where separately patented.

The commercial relevance of excipient patents depends on claim construction. A patent claiming a broad antibody formulation with histidine, sucrose, and polysorbate 80 could create a more meaningful barrier than a narrow claim limited to a specific concentration or stability result. A biosimilar sponsor may avoid a formulation claim by using a different buffer, sugar, surfactant, concentration, or container system.

The public patent landscape for an approved biologic should be reviewed through U.S. Patent and Trademark Office records, FDA Purple Book information, international patent registers, and litigation filings. LIBTAYO is a biologic, so the FDA Orange Book is not the primary patent reference. The Purple Book and BPCIA patent-exchange process are more relevant than the small-molecule Orange Book framework.

When does LIBTAYO lose regulatory exclusivity?

LIBTAYO received its first U.S. FDA approval on September 28, 2018, for metastatic or locally advanced cutaneous squamous cell carcinoma in patients unsuitable for curative surgery or radiation. Under the Biologics Price Competition and Innovation Act, a reference biologic generally receives 12 years of reference-product exclusivity from first licensure.

Milestone	Date or status
U.S. first approval	September 28, 2018
Twelve-year reference-product exclusivity	Approximately September 28, 2030
Biosimilar application timing	Generally no earlier than four years after first licensure
Current regulatory pathway	Biologics license application
Small-molecule generic pathway	Not applicable
Primary competitive mechanism	Biosimilar or interchangeable biosimilar

The 12-year exclusivity period does not eliminate patent barriers. A biosimilar sponsor may file and pursue approval before the end of all patent terms, but commercial launch depends on patent resolution, settlement, license rights, or an acceptable non-infringement and validity position.

What are the LIBTAYO patent expiration risks?

The core patent risk is likely to extend beyond the statutory biologic-exclusivity date. Publicly reported patent landscapes for cemiplimab include composition, antibody, formulation, and therapeutic-use rights that may extend into the mid-2030s, subject to patent-specific expiration dates, patent-term adjustment, terminal disclaimers, and jurisdiction.

A practical risk map is:

Protection category	Expected competitive relevance
Antibody composition and sequence	Highest barrier if valid and enforceable
Formulation patents	Important where the commercial formulation is difficult to design around
Method-of-use patents	Relevant for specific tumor types, lines of therapy, or combinations
Manufacturing patents	May constrain cell culture, purification, or process-specific approaches
Device or presentation patents	Usually narrower, but relevant to prefilled or subcutaneous products
Regulatory exclusivity	Blocks biosimilar approval reliance until the statutory period ends

Patent strength is highest where the claims cover the antibody itself or a required therapeutic use. Formulation patents are generally more vulnerable to design-around strategies, especially when the biosimilar can use different excipients while maintaining comparable quality and clinical performance.

How strong is the LIBTAYO biosimilar barrier?

The biosimilar barrier is moderate to high before the mid-2030s and should become more contestable after reference-product exclusivity expires. The main barriers are:

• Complex analytical characterization of an IgG4 antibody.
• Need to establish similarity across structure, purity, potency, glycosylation, aggregation, and charge variants.
• Potential immunogenicity differences caused by formulation or process changes.
• Patent litigation under the BPCIA.
• Manufacturing scale and yield.
• Oncology pricing pressure.
• Provider and payer substitution dynamics.
• Interchangeability requirements if automatic pharmacy substitution is sought.

The excipient strategy can affect biosimilar development in two opposing ways. A conventional histidine-sucrose-polysorbate system is easier to reproduce because it has extensive industry precedent. At the same time, it may create formulation-patent exposure if the reference sponsor has broad claims covering the commercial composition.

A biosimilar using a different excipient system would need to establish that the change does not alter product quality, pharmacokinetics, immunogenicity, or clinical performance. In many cases, matching the reference excipient profile can reduce development risk but increase patent risk.

What is the FDA regulatory status of LIBTAYO?

LIBTAYO is FDA-approved for multiple oncology indications, including:

• Cutaneous squamous cell carcinoma.
• Basal cell carcinoma in specified settings.
• Non-small cell lung cancer in specified first-line settings.
• Cervical cancer in specified recurrent or metastatic settings.

The label has expanded through supplemental approvals based on clinical data in different tumor types and treatment lines. Each new indication can increase the value of method-of-use patents, but it does not restart the 12-year biologic reference exclusivity period.

The product remains administered by intravenous infusion. There is no FDA-approved subcutaneous LIBTAYO presentation identified in the cited labeling.

Which companies are challenging LIBTAYO, and what is the litigation outlook?

Publicly visible competitive pressure is currently more likely to arise from future biosimilar development than from conventional generic entry. Potential competitors include large biosimilar companies, oncology-focused manufacturers, and contract developers with antibody manufacturing capacity.

Relevant competitor groups include:

• Amgen.
• Biocon Biologics.
• Celltrion.
• Samsung Bioepis.
• Sandoz.
• Fresenius Kabi.
• Pfizer.
• Teva.
• Coherus.
• Large Chinese and European antibody manufacturers.

A current, complete list of LIBTAYO Paragraph IV challengers is not applicable in the conventional sense because Paragraph IV is a Hatch-Waxman mechanism for small-molecule drugs. Biosimilar applicants instead proceed under the BPCIA framework and may engage in the statutory patent-information exchange and litigation process.

No broad commercial biosimilar launch threat should be assumed solely from the existence of competing PD-1 antibodies. Pembrolizumab, nivolumab, dostarlimab, and atezolizumab compete clinically, but they are not biosimilars of cemiplimab.

How does LIBTAYO compare with competing PD-1 and PD-L1 drugs?

Product	Target	Current delivery model	Key formulation implication
LIBTAYO	PD-1	Intravenous infusion	Conventional liquid antibody formulation
KEYTRUDA	PD-1	Intravenous infusion	Large oncology franchise and future biosimilar pressure
OPDIVO	PD-1	Intravenous infusion and other approved regimens	Broad indication base and combination use
JEMPERLI	PD-1	Intravenous infusion	Smaller franchise with gynecologic-oncology concentration
TECENTRIQ	PD-L1	Intravenous and subcutaneous formulation in certain markets/contexts	Demonstrates commercial value of alternative administration
IMFINZI	PD-L1	Intravenous infusion	Broad lung and hepatobiliary oncology use

The principal formulation differentiator in this class is administration convenience, not the basic excipient platform. A subcutaneous product could improve treatment-center economics and support differentiation after intravenous biosimilar competition begins.

What is the commercial exposure for Regeneron and Sanofi?

LIBTAYO is commercialized under the Regeneron-Sanofi collaboration. Regeneron assumed full global responsibility for LIBTAYO under a restructuring of the collaboration, with Sanofi retaining economic participation through royalties under the revised arrangement (Regeneron Pharmaceuticals, 2022; Sanofi, 2022).

Regeneron reported LIBTAYO net product sales of approximately $923 million in 2023, compared with approximately $748 million in 2022 (Regeneron Pharmaceuticals, 2024). The product’s commercial exposure is tied to:

• Expansion of first-line non-small cell lung cancer use.
• Growth in cutaneous squamous cell carcinoma and basal cell carcinoma.
• Competition from other checkpoint inhibitors.
• Reimbursement and treatment-site economics.
• Future biosimilar timing.
• Patent and regulatory exclusivity.
• Potential lifecycle products using lower-volume or subcutaneous delivery.

Excipient improvements that reduce waste, extend in-use stability, or simplify pharmacy preparation could create value even without changing the clinical dose. Their commercial impact would depend on whether the sponsor can secure new regulatory protection, obtain provider adoption, and avoid substantial manufacturing-cost increases.

What licensing and partnering opportunities exist?

The most credible licensing opportunities are concentrated in enabling technologies rather than in the basic excipients themselves.

Formulation and delivery

Potential partners could license:

• High-concentration antibody formulation platforms.
• Low-viscosity excipient systems.
• Low-peroxide surfactant technology.
• Subcutaneous delivery devices.
• Prefilled syringe or wearable-injector systems.
• Lyophilization and rapid-reconstitution technology.

Manufacturing and supply

Other opportunities include:

• Qualified polysorbate 80 supply.
• Single-use bioprocessing components.
• Closed-system transfer devices.
• Analytical assays for aggregates, particles, oxidation, and surfactant degradation.
• Regional fill-finish capacity.
• Biosimilar CMC and comparability services.

The highest-value technology would combine formulation stability with a commercially practical delivery format. A formulation that improves stability but requires expensive devices or complex cold-chain handling may have limited net value.

What generic launch scenarios exist for LIBTAYO?

Three launch scenarios are most relevant:

1. Patent-constrained launch after reference-product exclusivity but before all patents expire, if the sponsor settles or licenses.
2. First biosimilar launch after key composition and formulation barriers weaken, with discounts initially below branded oncology pricing.
3. Multiple-biosimilar entry after the principal patent estate expires, creating greater price erosion and payer-driven substitution.

The first entrant may benefit from contracting advantages and physician familiarity, but oncology biosimilar markets can become crowded rapidly. A differentiated presentation, such as a ready-to-administer or subcutaneous product, could support premium positioning relative to a standard intravenous biosimilar.

Key Takeaways

• LIBTAYO is a 50 mg/mL intravenous cemiplimab-rwlc solution supplied in a 350 mg/7 mL single-dose vial.
• Its core excipient system contains histidine buffer, sucrose, and polysorbate 80.
• The formulation is conventional, clinically validated, and relatively reproducible for biosimilar developers.
• Commercial opportunities are strongest in subcutaneous delivery, lower-volume presentations, ready-to-administer formats, surfactant quality, and manufacturing services.
• LIBTAYO’s 12-year U.S. biologic exclusivity period runs approximately through September 2030.
• Patent protection may extend into the mid-2030s, depending on the specific patent family and jurisdiction.
• Paragraph IV analysis is not the correct framework for LIBTAYO because it is a biologic rather than a Hatch-Waxman small molecule.
• Formulation patents may be designed around more readily than antibody composition or core therapeutic-use patents.
• Regeneron reported approximately $923 million in LIBTAYO net product sales in 2023.
• A differentiated delivery system could delay price erosion and create lifecycle value after biosimilar entry.

FAQs

Can a LIBTAYO biosimilar use different excipients?

Yes. A biosimilar does not automatically have to copy every excipient, but any difference must be supported by analytical, pharmacokinetic, immunogenicity, and clinical comparability data as required by FDA review.

Is polysorbate 80 the main formulation risk in LIBTAYO?

It is a significant risk area because polysorbate degradation can generate peroxide-related impurities and contribute to protein oxidation or particles. The risk depends on grade, storage, container interaction, and the complete formulation.

Could LIBTAYO be reformulated for subcutaneous injection?

Potentially, but the current intravenous formulation is not evidence that a subcutaneous product is feasible. Development would require high-concentration stability, viscosity control, injection-device compatibility, local tolerability, and clinical validation.

Does the Orange Book list LIBTAYO patents?

The Orange Book is not the primary patent source for LIBTAYO because LIBTAYO is a biologic. The Purple Book, USPTO records, BPCIA disclosures, patent litigation filings, and international registers are more relevant.

Which excipient suppliers could benefit from LIBTAYO biosimilar development?

Suppliers of pharmaceutical-grade histidine, sucrose, low-peroxide polysorbate 80, alternative surfactants, sterile single-use components, and analytical testing services could benefit as biosimilar developers build manufacturing and comparability packages.

References

1. Regeneron Pharmaceuticals, Inc. (2022). Regeneron and Sanofi restructure antibody collaboration to provide Regeneron full global responsibility for Libtayo.
2. Regeneron Pharmaceuticals, Inc. (2024). 2023 annual report.
3. Sanofi. (2022). Sanofi and Regeneron restructure antibody collaboration.
4. U.S. Food and Drug Administration. (2018). FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma.
5. U.S. Food and Drug Administration. (2024). LIBTAYO (cemiplimab-rwlc) prescribing information.
6. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
7. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, §7002.